Science Explorer Back to mapMap
Discussion
Company · Elmsford · United States

TechnoVax (United States)

technovax.comROR OpenAlex
Research works
6
▲ 39% vs 2018-21
Citations
296
50.2 per fractional work
Top-10% rate
0.5%
all institutions 10.0%
Open access
69%
world 40%
International
10%
world 18%
TechnoVax (United States)

Not ranked overall: TechnoVax (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does TechnoVax (United States) work in?

In all years, 63% of research at TechnoVax (United States) is in Health Sciences, 36% in Life Sciences. Its largest fields are Medicine (63%), Biochemistry, Genetics and Molecular Biology (23%), Agricultural and Biological Sciences (7%). It does 1.5× the world's share of Health Sciences.

Health Sciences: 4 fractional works · 62.8% of its workMedicine: 4 fractional works · 62.8% of its workEpidemiology: 2 fractional works · 26.1% of its workInfectious Diseases: 1 fractional works · 23.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 7.4% of its workOncology: 0 fractional works · 1.4% of its workSurgery: 0 fractional works · 1.4% of its workObstetrics and Gynecology: 0 fractional works · 1.0% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.0% of its workReproductive Medicine: 0 fractional works · 1.0% of its workLife Sciences: 2 fractional works · 36.2% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 23.0% of its workMolecular Biology: 1 fractional works · 13.9% of its workGenetics: 0 fractional works · 8.1% of its workCancer Research: 0 fractional works · 1.0% of its workAgricultural and Biological Sciences: 0 fractional works · 6.8% of its workAnimal Science and Zoology: 0 fractional works · 6.8% of its workImmunology and Microbiology: 0 fractional works · 6.4% of its workImmunology: 0 fractional works · 6.4% of its workPhysical Sciences: 0 fractional works · 1.0% of its workChemistry: 0 fractional works · 1.0% of its workSpectroscopy: 0 fractional works · 1.0% of its workALL ITS WORKTechnoVax (UnitedStates)6fractional works, all years
Life Sciences36%Physical Sciences1%Health Sciences63%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Medicine462.8%
    1. Biochemistry, Genetics and Molecular Biology123.0%
    2. Agricultural and Biological Sciences06.8%
    3. Immunology and Microbiology06.4%
    1. Chemistry01.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Who are the top researchers at TechnoVax (United States)?

Ranked on the quality score, Jose M. Galarza lead among researchers whose main affiliation is TechnoVax (United States).

  1. 1 Jose M. Galarza United States · #1,328,132 worldwide 1.2k citations · 25 works
All ranked researchers at TechnoVax (United States)

What are the most cited papers from TechnoVax (United States)?

The most cited paper from TechnoVax (United States) is "Zika virus-like particle (VLP) based vaccine" (Hélène Boigard, Alexandra Alimova, George R. Martin et al., 2017), with 162 citations. Next come "Adjuvant formulations for virus-like particle (VLP) based vaccines" (145) and "A Novel Intranasal Virus-Like Particle (VLP) Vaccine Designed to Protect against the Pandemic 1918 Influenza A Virus (H1N1)" (59).

Most cited papers
#PaperReleasedCitations
1 Zika virus-like particle (VLP) based vaccine Hélène Boigard, Alexandra Alimova, George R. Martin et al. · PLoS neglected tropical diseases Open access 8 May 2017 162
2 Adjuvant formulations for virus-like particle (VLP) based vaccines Velasco Cimica, Jose M. Galarza · Clinical Immunology Open access 3 Aug 2017 145
3 A Novel Intranasal Virus-Like Particle (VLP) Vaccine Designed to Protect against the Pandemic 1918 Influenza A Virus (H1N1) Demetrius Matassov, Albert Cupo, Jose M. Galarza · Viral Immunology Sep 2007 59
4 Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein Velasco Cimica, Hélène Boigard, Bipin Bhatia et al. · Clinical and Vaccine Immunology Open access 31 Mar 2016 41
5 Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature Hélène Boigard, Velasco Cimica, Jose M. Galarza · Vaccine Open access 28 Oct 2018 37
All 13 most cited papers, with filters and sorting

Which research topics does TechnoVax (United States) publish most on?

By volume in 2022-now: Virus-based gene therapy research, Viral Infectious Diseases and Gene Expression in Insects, CRISPR and Genetic Engineering and Viral gastroenteritis research and epidemiology.

Virus-based gene therapy…0Virus-based gene therapy research: 0 fractional worksViral Infectious Diseases and Gene Expression in Insects: 0 fractional worksCRISPR and Genetic Engineering: 0 fractional worksViral gastroenteritis re…0Viral gastroenteritis research and epidemiology: 0 fractional worksCancer-related molecular mechanisms research: 0 fractional worksEndometrial and Cervical Cancer Treatments: 0 fractional worksExtracellular vesicles in disease: 0 fractional worksCAR-T cell therapy research: 0 fractional worksCOVID-19 Clinical Research Studies: 0 fractional worksSARS-CoV-2 and COVID-19 Research: 0 fractional works
GeneticsMolecular BiologyInfectious DiseasesCancer Research2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Virus-based gene therapy research Genetics 0 works
  2. 2 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
  3. 3 CRISPR and Genetic Engineering Molecular Biology 0 works
  4. 4 Viral gastroenteritis research and epidemiology Infectious Diseases 0 works
  5. 5 Cancer-related molecular mechanisms research Cancer Research 0 works
  6. 6 Endometrial and Cervical Cancer Treatments Obstetrics and Gynecology 0 works
  7. 7 Extracellular vesicles in disease Molecular Biology 0 works
  8. 8 CAR-T cell therapy research Oncology 0 works
  9. 9 COVID-19 Clinical Research Studies Infectious Diseases 0 works
  10. 10 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available69.3%not open30.7%

World: 40% of research is openly available.

with international co-authors10.0%domestic only90.0%

World: 18% is written across borders.

How has TechnoVax (United States)'s research output changed?

Output in 2022-2025 was 39% higher than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Elmsford

All research institutions in Elmsford

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about TechnoVax (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.